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Several enzymes and metabolites of the kynurenine pathway (KP) have
immunomodulatory effects. Modulation of the activities and levels of these molecules
might be of particular importance under disease conditions when the amelioration of
overreacting immune responses is desired. Results obtained by the use of animal and
tissue culture models indicate that by eliminating or decreasing activities of key enzymes
of the KP, a beneficial shift in disease outcome can be attained. This review summarizes
experimental data of models in which IDO, TDO, or KMO activity modulation was
achieved by interventions affecting enzyme production at a genomic level. Elimination of
IDO activity was found to improve the outcome of sepsis, certain viral infections, chronic
inflammation linked to diabetes, obesity, aorta aneurysm formation, and in anti-tumoral
processes. Similarly, lack of TDO activity was advantageous in the case of anti-tumoral
immunity, while KMO inhibition was found to be beneficial against microorganisms and
in the combat against tumors, as well. On the other hand, the complex interplay among
KP metabolites and immune function in some cases requires an increase in a particular
enzyme activity for the desired immune response modulation, as was shown by the
exacerbation of liver fibrosis due to the elimination of IDO activity and the detrimental
effects of TDO inhibition in a mouse model of autoimmune gastritis. The relevance of
these studies concerning possible human applications are discussed and highlighted.
Finally, a brief overview is presented on naturally occurring genetic variants affecting
immune functions via modulation of KP enzyme activity.
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INTRODUCTION
The kynurenine pathway (KP) is the main route of Trp metabolism. The enzymes of the pathway
generate numerous metabolites, some of which are pro-inflammatory and/or generate free radicals,
while others are known to be anti-inflammatory and/or scavenge free-radicals. Strong links between
KP function and the immune system are demonstrated by extensive amounts of data on changes
in the levels of KP metabolites and enzyme activities in diseases accompanied by alterations in
immune function. Also, inflammatory cytokines are known to enhance the expression of a key
KP enzyme, indoleamine 2,3-dioxygenase (IDO). Imbalances in the pathway can be detrimental,
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as excessive production of either pro-, or anti-inflammatory
metabolites can contribute to the development of autoimmunity
and/or lead to inefficient immune response against pathogens.
Therefore, the understanding of how the KP changes in
different immunological states, and, the reverse, how KP effects
immunological responses, is cardinal both for understanding
the true nature of specific diseases and for identification of
therapeutic targets. Genetic manipulations leading either to
enhancement or inhibition of the expression of KP enzymes
might be a feasible way of restoring the imbalance of the pathway
in various diseases. Naturally occurring genetic variations in the
coding regions in several genes coding for KP enzymes have
been identified [for a review see (1)]. In the majority of these,
however, a causal relation between a specific gene variant and
disease development has not been elucidated.
This review summarizes available data on the effects of
expression modification of KP enzyme coding genes with specific
attention to immune modulation. Following a brief overview
Abbreviations: KP, kynurenine pathway; IDO, indoleamine 2,3-dioxygenase
(protein); IDO, indoleamine 2,3-dioxygenase (gene in human); Ido, indoleamine
2,3-dioxygenase (murine gene); TDO, tryptophan 2,3-dioxygenase (protein);
Tdo, tryptophan 2,3-dioxygenase (murine gene); TDO, tryptophan 2,3-
dioxygenase (gene in human); KMO, kynurenine 3-monooxygenase (protein);
KMO, kynurenine 3-monooxygenase (gene in human); Kmo, kynurenine
3-monooxygenase (murine gene); CNS, central nervous system; L-KYN, L-
kynurenine; KYNA, kynurenic acid; KATI-IV, kynurenine aminotransferases;
NMDAR, N-methyl-D-aspartate receptor; α7nAChRs, nicotinic acetylcholine
receptors; KYNU, kynureninase; AA, anthranilic acid; 3-HK, 3-hydroxy
kynurenine; XA, xanthurenic acid; 3-HAA, 3-hydroxyanthranilic acid; ACMS,
2-amino-3-carboxymuconate-semialdehyde; 3-HAO, 3-hydroxyanthranilate
3,4-dioxygenase; PIC, picolinic acid; ACMSD, aminocarboxymuconate-
semialdehyde-decarboxylase; QUIN, quinolinic acid; ISRE, IFN stimulated
response element; GAS, gamma-activated sequences; DRE, dendritic cell response
element; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B-cells;
TLRs, toll-like receptors; TGFBR, transforming growth factor beta receptor;
AHR, aryl hydrocarbon receptor; IFNBR, interferon beta receptor; IFNGR,
interferon gamma receptor; TNFR, tumor necrosis factor receptor; SOCS3,
suppressor of cytokine signaling 3; DC, dendritic cell; IFN, interferon; LPS,
lipopolysaccharide; IL, interleukines; TNF, tumor necrosis factor; mTOR,
mammalian target of rapamycin; NPC, nasopharyngeal carcinoma; AML, acute
myeloid leukemia; AHR, aryl hydrocarbon receptor; ROS, reactive oxygen species;
siRNA, small interfering RNA; IDO−/−, IDO knockout; UPEC, Uropathogenic
Escherichia coli; MuLV, murine leukemia virus; NK cell, natural killer cell; pDC,
plasmocytoid dendritic cell; WT, wild type; ECMV, encephalomyocarditis virus;
sJIA, systemic juvenile idiopathic arthritis; sHLH, secondary hemophagocytic-
lymphohistiocytosis; STING, Stimulator of Interferon Genes; DNP, DNA
nanoparticle; EAE, experimental autoimmune encephalitis; MS, multiple sclerosis;
MOG, myelin oligodendrocyte glycoprotein; c-diGMP, cyclic diguanylate
monophosphate; CIA, collagen induced arthritis; RA, rheumatoid arthritis;
AdIDO, adenoviral vector-mediated IDO gene delivery; NOD, non-obese
diabetic; MRLlpr/lpr, Lupus-prone Murphy Roths large mice; SLE, systemic
lupus erythematosus; MAS, macrophage activation syndrome; DR, diabetic
retinopathy; AngII, angiotensin II; ApoE−/−, Apolipoprotein E knockout;
NAD(P)H, nicotinamide adenine dinucleotide phosphate; AAA, abdominal aortic
aneurysm; VSMC, vascular smoothmuscle cell; Ldlr−/−, low density lipoprotein—
receptor deficient; HFD, high fat diet; MMP2, matrix metallopeptidase 2; WAT,
white adipose tissue; OGTT, oral glucose tolerance test; ITT, insulin tolerance
test; IAA, indole-3 acetic acid; CCl4, carbon-tetrachloride; PMN, polymorph
nuclear neutrophil; S.t., Salmonella typhimurium; shRNA, short hairpin RNA; RT,
radiotherapy; BER, base excision repair; MX, methoxyamine; TS, thymidylate
synthase; IRI, ischemia-reperfusion injury; AKI, acute kidney injury; CTL,
cytolytic T lymphocyte; PD, Parkinson’s disease; SSc, systemic sclerosis; CD,
Crohn’s disease; BM, bacterial meningitis; CSF, cerebro-spinal fluid.
of the metabolites and enzymes of the pathway, we summarize
observations which indicate links between KP and immune
function. This is followed by an overview of findings obtained
by the use of models with targeted ablation and up- or down-
regulation of KP enzymes. With respect to diseases related to
disorders of the immune system, such as infectious diseases,
chronic inflammation, autoimmunity and cancer, these models
have focused on three KP enzymes: IDO, tryptophan 2,3-
dioxygenase (TDO) and kynurenine 3-monooxygenase (KMO)
(Tables 1–5). These enzymes and, in particular, IDO are also
targeted by several pharmacochemical interventions. Discussion
of that field is out of the scope of this review, as we focus on
gene level interventions. Readers interested in pharmacologic
interventions of KP enzymes can find excellent summaries of the
field in Ye et al. (45) and Lemos et al. (46). In the final section,
we provide a summary of available data on those naturally
occurring KP gene variants which are believed to be associated
with different human diseases affecting immune function.
KYNURENINE PATHWAY—THE MAIN
ROUTE OF TRYPTOPHAN METABOLISM
Disregarding protein synthesis, the KP is the main route of Trp
metabolism, both in the peripheral and in the central nervous
system (CNS) (Figure 1). In the CNS, 95 percent of the resident
Trp is metabolized via the KP, and only the minority of the amino
acid is transformed into serotonin and melatonin. In consecutive
steps of the pathway, numerous metabolites possessing immune-
and neuromodulatory properties are synthesized (47).
The first and rate limiting step of Trp metabolism is the
conversion of the amino acid into N-formyl-L-kynurenine. This
step is catalyzed by one of three enzymes: IDO (often referred to
as IDO1), IDO2, or TDO. (Prior to the discovery of IDO 2, “IDO”
designation was used exclusively. Today IDO and IDO1 are used
as synonyms and IDO2 is reserved for the enzyme recognized
in 2007. In this review we will use IDO unless we are referring to
IDO2). TDO is expressedmainly in the liver, thus plays a cardinal
role in regulating the amount of available Trp throughout the
body, outside the CNS. IDO is expressed in several human
tissues, among them various cell types of the immune system
(48). The enzyme plays a key role in reactions leading to the
synthesis of immunoactive KP metabolites, consequently its role
in immunomodulation is expected. IDO2 expression pattern and
function is not known in detail. A strong argument against the
role of this enzyme in Trp metabolism is the frequent occurrence
of an IDO2 gene variant that gives rise to a non-functioning
enzyme (49), and the high Michaelis Constant of the enzyme for
Trp, which is 100-fold above the physiological concentrations of
the amino acid (50).
N-formyl-L-kynurenine is converted to L-kynurenine (L-
KYN) by formamidase. L-KYN is an important branch point
of the KP as it can be alternatively metabolized into three
different metabolites of which some are neurotoxic, while
others possess neuroprotective and antioxidant properties
(51, 52). Firstly, L-KYN can be metabolized into kynurenic
acid (KYNA) by kynurenine aminotransferases (KATI-IV)
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TABLE 1 | Effects of modulation of IDO function by genetic manipulation in in vivo and in vitro models of systemic inflammation, viral, and bacterial infections.
Gene Type of genetic
modulation
Disease modeled Study design Effect of gene modulation References
IDO IDO−/− Systemic inflammation Mouse model of LPS induced
sepsis
Restoration of imbalance of pro-and
anti-inflammatory cytokines,
increased survival rate
(2)
IDO−/− Viral infection Murine leukemia virus induced
murine AIDS model
Decreased virus replication; increased
number of pDCs and increased type I
IFN production; increased survival
rate following Toxoplasma gondii
infection
(3)
IDO−/− Viral infection ECMV induced mouse model of
acute viral myocarditis
Decreased virus replication and
myocardium necrosis; higher survival
rate
(4)
IDO−/− Pain hypersensitivity related
to viral infection
Pain hypersensitivity induced by
Influenza A virus and MuLV infection
Diminished acute and chronic pain
sensitivity related to influenza A and
MuLV infections, respectively
(5)
IDO
overexpression
Viral infection HeLa cells transfected with
pcDNA3-IDO
Overexpression of IDO prior to viral
infection diminished viral replication
thus decreasing infection spread to
the neighboring cells
(6)
IDO−/− Viral infection LP-BPM5 retrovirus infection of
mice - a model of murine AIDS
Gene knockout did not have any
effect on disease progression and
viral load
(7)
IDO−/− Bacterial infection Mouse model of Mycobacterium
tuberculosis infection
In vitro findings showed enhanced T
cell proliferation after infection,
however, in vivo no significant
difference could be observed in
survival rate or in the number of
activated T cells
(8)
IDO−/− Bacterial infection Murine cystitis model provoked by
uropathogen Escherichia coli
infection
Increased levels of pro-inflammatory
cytokines, higher granulocyte
accumulation, and local inflammation
of the bladder and decreased survival
of the extracellular bacteria
(9)
IDO−/− Bacterial infection Mouse model of Rhodococcus equi
infection
Decreased levels of TGFβ and FOXP3
expression in the liver tissue indicating
reduced T regulatory cell responses
and prolonged liver inflammation
(10)
IDO, Indoleamine 2,3-dioxygenase gene; IDO−/−, IDO knockout; pDC, plasmocytoid dendritic cell; IFN, interferon; ECMV, encephalomyocarditis virus; MuLV, murine leukemia virus;
TGFβ, transforming growth factor beta; FOXP3, forkhead box P3.
from which KATII plays the most important role in the
human CNS (53, 54). Secondly, L-KYN is also a substrate
of kynureninase (KYNU), an enzyme responsible for the
formation of anthranilic acid (AA). Finally, the third route of
L-KYN metabolism is catalyzed by KMO to form 3-hydroxy
kynurenine (3-HK) which can be further transformed into
xanthurenic acid (XA) by KATs. 3-HK and AA can both be
metabolized into 3-hydroxyanthranilic acid (3-HAA), which,
alongside with 3-HK, have free-radical generating properties,
thus can lead to oxidative stress and neurodegeneration
(55). However, depending on the redox properties of
the cell, 3-HK and 3-HAA can also serve as antioxidant
molecules (56).
Further down the pathway, the unstable 2-amino-3-
carboxymuconate-semialdehyde (ACMS) is formed by
3-hydroxyanthranilate 3,4-dioxygenase (3-HAO). ACMS
can be transformed either into picolinic acid (PIC) by an
aminocarboxymuconate-semialdehyde-decarboxylase (ACMSD)
catalyzed reaction, or it can form the NAD+ and NADP+
precursor quinolinic acid (QUIN) via a non-enzymatic
conversion. QUIN is a key figure in excitotoxicity mediated
neurodegeneration (52, 57, 58).
In light of the numerous enzymes participating and
metabolites generated, the involvement of the KP in various
disorders is not surprising. Indeed, changes in KP enzyme activity
and metabolite levels have been detected in inflammatory,
autoimmune, neurodegenerative and psychiatric diseases, as well.
In the following sections of this review we will briefly consider
observations that point to existing links between KP and immune
function. Then we will overview results obtained by models in
which the KP was modulated by interventions effecting gene
activity. Finally, we list known genetic alterations in genes of
KP enzymes that are believed to be associated with changes in
immune functions.
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TABLE 2 | Effects of modulation of IDO function by genetic manipulation in animal models of allergy and autoimmunity.
Gene Type of genetic
modulation
Disease modeled Study design Effect of gene modulation References
IDO IDO−/− Airway allergy Mouse model of acute and chronic
allergic airway inflammation
Decrease in Th2 response upon
exposure to allergen: diminished Th2
cell activation, Th2 cytokine
production, decreased airway
inflammation, mucus secretion, and
airway hyperresponsiveness
(11)
IDO−/− Autoimmunity Mice models of sJIA, MAS and
sHLH
No difference in the symptoms of
IDO−/− animals compared to
WT—possibility of the presence of
other Trp metabolizing enzymes
restoring the absence of Ido
(12)
IDO−/− Autoimmunity EAE mouse model of MS Immunization with MOG, systemic
treatment with DNPs or c-diGMP
induced STING signaling, thus potent
regulatory immune responses could
be achieved, leading to restrained
EAE severity and delayed disease
onset. However, in the case of lack of
IDO in hematopoietic cells, no
therapeutic response could be
observed
(13)
IDO−/− Autoimmunity EAE mouse model of MS Exacerbated EAE disease severity,
increased encephalitogenic Th1 and
Th17 responses and diminished Treg
responses in IDO−/− animals.
(14)
IDO−/− Autoimmunity CIA mouse model of RA More severe disease demonstrated
by increased erosion and cellular
infiltration of the joints of IDO−/−
animals, higher production of IFNγ
and IL-17 in the lymph nodes and
higher Th1 and Th17 cell frequency in
paws
(15)
AdIDO Autoimmunity CIA rat model of RA Significant reduction of bony
destruction, soft tissue swelling and
synovial hyperplasia, indicating
decreased disease severity
(16)
Transfection with
Ido
Autoimmunity NOD mouse model of T1D After TGFβ treatment production of
pro-inflammatory cytokines (IL-6 and
TNFα) was decreased and pancreatic
β-cell auto-antigen generation was
diminished
(17)
IDO−/− Autoimmunity MRLlpr/lpr mouse model of SLE The injection of apoptotic thymocytes
in IDO−/− MRLlpr/lpr animals caused
elevation of autoantibody titers,
pro-inflammatory cytokine production
and dysregulated T cell responses
leading to lethal autoimmunity due to
renal failure
(18)
IDO, Indoleamine 2,3-dioxygenase gene; IDO−/−, IDO knockout; sJIA, systemic juvenile idiopathic arthritis; MAS, macrophage activation syndrome; sHLH, secondary hemophagocytic-
lymphohistiocytosis; WT, wild type; Trp, tryptophan; EAE, experimental autoimmune encephalitis; MS, multiple sclerosis; MOG, myelin oligodendrocyte glycoprotein; DNP, DNA
nanoparticle; c-diGMP, cyclic diguanylate monophosphate; CIA, collagen induced arthritis; RA, rheumatoid arthritis; IFNγ, interferon gamma; AdIDO, adenoviral vector-mediated IDO gene
delivery; NOD, non-obese diabetic; T1D, type 1 diabetes; TGFβ, transforming growth factor beta; MRLlpr/lpr, Lupus-proneMurphy Roths large mice; SLE, systemic lupus erythematosus.
OBSERVATIONS INDICATING LINKS
BETWEEN THE KYNURENINE PATHWAY
AND IMMUNE FUNCTIONS
Indoleamine 2,3-Dioxygenase
Interplay between several enzymes of the KP and immune
function are well-demonstrated. In this respect IDO, a key
enzyme of the pathway, deserves particular attention. IDO is
believed to exert its effects on immune function both by direct
and indirect mechanisms. As an enzyme, IDO plays a role in
Trp utilization and through this, in cellular metabolism via
mTOR and GCN2 linked pathways. By converting Trp to KYN,
IDO has a central role in determining concentrations of KP
metabolites, many of which are direct or indirect regulators
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TABLE 3 | Effects of modulation of IDO function by genetic manipulation in transplant animal models.
Gene Type of genetic
modulation
Disease modeled Study design Effect of gene modulation References
IDO Adenoviral Ido
gene transfer
Transplantation Adenoviral gene transfer into
pancreatic islets; transplantation
into diabetogenic mice
Prolonged survival of transplanted
tissue; depletion of local Trp; inhibition
of T cell proliferation
(19)
EIAV based Ido
gene transfer
Transplantation Mouse model of corneal transplant Prevention of allogeneic T cell
responses; prolonged corneal graft
survival
(20)
hIDO gene transfer
via PEI
Transplantation Rat model of lung transplant Blockage of local T cell responses,
inhibition of intracellular ROS
formation, thus reducing necrosis and
apoptosis of lung cells
(21)
hIDO gene transfer
via PEI
Transplantation Rat model of lung transplant Selective decrease of complex I
activity of the electron transport chain,
leading to decreased ATP production
in the lung infiltrating T cells, causing
damage in their cytotoxic properties
(22)
Sleeping beauty
transposon
mediated hIDO
delivery
Transplantation Rat model of lung transplant,
investigation of lung fibrosis
Diminished collagen deposition in
IDO+/+ lungs, resulting in a more
preserved bronchus-alveolar
architecture. In vitro findings revealed
that IDO+/+ lung cells inhibited the
TGFβ mediated proliferation of
fibroblasts
(23)
adenoviral Ido
gene transfer
Transplantation Rat model of skin transplant Wounds with IDO expressing
fibroblast healed faster than those
with IDO−/− fibroblasts due to
enhanced capillary formation
(24)
adenoviral Ido
gene transfer
Transplantation Rat model of cardiac allograft
survival
Decreased infiltration of the cardiac
allograft with monocytes,
macrophages and T cells,
accompanied by diminished intragraft
levels of IFNγ, TNFα, TGFβ, IL-1β,
resulting in prolonged graft survival
(25)
PEI carrier hIDO
transfer
Transplantation Mouse model of lung
transplantation
Prolonged graft survival due to
inhibited early T cell responses and
diminished memory T cell formation.
T cell inhibiting properties were found
to be due to the impairment of
calcium signaling of the cells
(26)
IDO, Indoleamine 2,3-dioxygenase gene; IDO−/−, IDO knockout; Trp, tryptophan; EIAV, Equine infectious anemia virus; PEI, polimer polyethilenimine; ROS, reactive oxygen species;
TGFβ, transforming growth factor beta; IFNγ, interferon gamma; TNFα, tumor necrosis factor alpha.
of immunofunction. Furthermore, IDO also acts as a signal
protein. In concert with TGFβ, it regulates activation through
non-canonical NF-κB response elements, thus affecting of its own
production as well (45, 46).
IDO production and activity is controlled at different levels,
including both transcriptional and post-translational regulation
[reviewed in (46, 59)] (Figure 2). At the protein level, both its
substrate, Trp, and its co-factor, heme, enhance IDO activity
(61, 62). NO was found to reversibly inhibit the enzyme by
binding to the active site (63, 64). Antioxidants also inhibit
enzyme activity, both at transcriptional and post-transcriptional
levels (62). Phosphorylation of two tyrosine side chains also can
modulate IDO activity and its halflife (65). Decrease in IDO
enzyme levels can be the result of ubiquitylation of the protein
by the suppressor of cytokine signaling 3 (SOCS3) factor and
proteosomal degradation (66).
At the level of transcription several cis-regulatory elements
in the IDO promoter transmit regulatory signals. These are
IFN stimulated response elements (ISRE), palindromic gamma-
activated sequences (GAS), dendritic cell response elements
(DRE) and non-canonical NF-κB binding sites [see reviews (60,
65)]. A number of transcription factors have been identified
so far, which bind to these elements and play roles in the
transcriptional regulation of IDO. Among them are IRF-1, IRF-
8, Stat1a, NF-κB (67) and aryl hydrocarbon receptor (AHR).
Recently, epigenetic regulation of the gene through histone
deacetylase activity has also been reported (68). Through these
factors various receptor-ligand pathways converge to determine
IDO gene expression. These transmit regulatory signals from
activated toll-like receptors (TLRs), transforming growth factor
beta receptors (TGFBRs), AHR, interferon beta and gamma
receptors (IFNBR and IFNGR), and members of the tumor
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TABLE 4 | Effects of modulation of IDO function by genetic manipulation in in vitro and in vivo models of chronic inflammation and cancer.
Gene Type of genetic
modulation
Disease modeled Study design Effect of gene modulation References
IDO IDO−/− Chronic inflammation Mouse model of DR Reduced retinal capillary degeneration (27)
IDO−/− Chronic inflammation AngII induced atherosclerosis
mouse model
Reduced ROS production; diminished
endothelial cell dysfunction and apoptosis
(28)
IDO−/− Chronic inflammation Mouse model of AAA: Ldlr−/− mice
infused with AngII and fed with HFD
Reduced VSMC apoptosis (29)
IDO−/− and siRNA
mediated Kynu
silencing
Chronic inflammation AngII induced AAA formation in
ApoE−/− mice
Protection against AAA
formation—decrease in elastic lamina
degradation and aortic expansion
(30)
IDO−/− Chronic inflammation Mouse model of obesity Lower body weight and fat mass;
increased number of M2
(anti-inflammatory) macrophages in the
WAT; protection against the development
of liver steatosis and insulin resistance;
diminished LPS plasma levels
(31)
IDO−/− Chronic inflammation CCl4 induced mouse model of
hepatic fibrosis
Aggravation of liver fibrosis: higher TNFα
producing macrophages in the liver; higher
TNFα and fibrogenic factor expression
(32)
IDO−/− Intestinal immunity Citrobacter rodentium-induced
colitis mouse model
Attenuated intestinal inflammatory
response: less edema, cellular infiltration,
epithelial damage and reduced intestinal
colonization of bacteria
(33)
IDO silencing via
siRNA
Tumor immunity B16F10 melanoma cells in vitro and
mouse model
Decrease in tumor size; prevention of T
cell apoptosis; restoration of host
antitumor immunity
(34)
IDO silencing via
shIDO-ST
Tumor immunity B16F10 melanoma mouse model Tumor growth is attenuated and the
number of lung metastases was
diminished
(35)
IDO silencing via
shRNA
Tumor immunity SKOV-3 human ovarian cancer cell
line and mouse model
Decrease in tumor growth, peritoneal
dissemination and ascites formation,
increase in the number of tumor infiltrating
NK cells in vivo; increased sensitivity to NK
cells in vitro
(36)
IDO silencing via
shRNA
Tumor immunity Genetic downregulation of IDO in
A549 human lung adenocarcinoma
cells
Enhanced sensitivity of cells to FK866,
MX, pemetrexed and gemcitabine therapy
(37)
IDO, Indoleamine 2,3-dioxygenase gene; Ido−/−, Ido knockout; Kynu, kynureninase gene; siRNA, small interfering RNA; shIDO-ST, shRNA: short hairpin RNA; DR, diabetic retinopathy;
AngII, Angiotensin II; AAA, abdominal aortic aneurysm; Ldlr−/−, low density lipoprotein—receptor deficient; HFD, high fat diet; ApoE−/−, Apolipoprotein E knockout; CCl4, carbon-
tetrachloride; ROS, reactive oxygen species; VSMC, vascular smooth cell; WAT, white adipose tissue; LPS, lipopolysaccharide; TNFα, tumor necrosis factor alpha; NK cell, natural killer
cell; MX, methoxyamine.
necrosis factor receptor superfamily (TNFRs). Activation of any
of these receptors by their ligands can trigger signaling pathways
that promote or maintain the expression of IDO. Consequently,
inflammatory signals, such as IFNs, lipopolysaccharides (LPS),
interleukins (ILs) (such as IL-1, IL-2, IL-27, IL-10) TNFs,
TGFs, and prostaglandins, can induce IDO production (69, 70).
Thus, induction of the enzyme can be very complex and cell
type specific [reviewed in (71)]. Moreover, some inflammatory
markers act synergistically to increase IDO production and
the types of cytokines affecting gene expression may differ
in various cell types. This might be reflected by seemingly
contradictory reports on the roles of particular ligands in IDO
induction. According to some data, IFNγ is one of the main
inducers of IDO expression (72). On the other hand, results
obtained in LPS induced systemic inflammatory rat model did
not support the role of IFNγ in IDO induction in the CNS
and a more important role for other inflammatory cytokines,
such as TNFα and IL-6, was proposed. Strengthening this
conclusion, in LPS-stimulated glial cell cultures an increase
of IDO expression was observed, accompanied by elevated
levels of TNFα and IL-6, but no IFNγ expression. Based on
these observations, it was concluded that IDO induction in the
CNS by LPS is not mediated by IFNγ (73). However, recent
findings strongly argue for the role of IFNs in the activation
of IDO expression. It was found that not IFNγ but IFNα
signaling was essential in enhancing IDO expression after B7
ligation of CTL4-Ig (74). IDO expression up-regulation via CpG
oligodeoxynucleotide binding to TLR9 was also IFNα dependent
(75). Futhermore, IDO expression was found to be upregulated
by cytosolic DNA via the STING/IFNαβ pathway (76). Thus, it
seems firmly established that type I IFNs play a cardinal role
in enhanced IDO gene expression with inflammatory signals
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TABLE 5 | Effects of modulation of TDO and KMO function by genetic manipulation in in vitro and in vivo models.
Gene Type of genetic
modulation
Disease modeled Study design Effect of gene modulation References
TDO Lack of Tdo
expression
Tumor immunity P815 mouse tumor model Slower tumor progression, higher number of
cytolytic T cells in the tumor
microenvironment
(38)
TDO−/− Autoimmunity EAE mouse model of MS Protective effects against neuronal loss in the
spinal cord
(39)
TDO expression Infection HeLa T-Rex cells transfected with
pcDNA4-Tdo vector containing
human liver TDO cDNA
Antiparasitic, antiviral, and antibacterial effect;
suppression of T cell proliferation
(40)
KMO KMO−/− Viral infection EMCV induced mouse model of
viral myocarditis
Higher survival rate of Kmo−/− animals;
decrease in the cellular infiltration of
marophages and neutrophiles in heart tissue
(41)
siRNA mediated
Kmo silencing
Autoimmunity Mouse model of autoimmune
gastritis
Disease exacerbation due to excessive Th17
cell formation
(42)
KMO−/− Chronic inflammation Diabetic mouse and zebrafish
models
Proteinuria related to the malfunctioning of
kidney podocytes (proposedly due to NAD+
depletion)
(43)
KMO−/− IRI IRI leading to AKI in a mouse model Decreased renal tubular necrosis and
neutrophil granulocyte infiltration
(44)
TDO, Tryptophan 2,3-dioxygenase gene; TDO-/-, TDO knockout; KMO, Kynurenine 3-monooxygenase gene; KMO-/-, KMO knockout; EAE, experimental autoimmune encephalitis; MS,
multiple sclerosis; EMCV, encephalomyocarditis virus; IRI, ischemia-reperfusion injury; AKI, acute kidney injury.
and that IDO expression following LPS treatment is induced by
type I IFNs.
IDO is expressed by numerous cells of the immune system:
monocytes, dendritic cells (DCs), macrophages and microglia
(48). It regulates immune responses in various direct and indirect
ways (Figure 3). On the one hand, by decreasing the amount
of available Trp, it causes an increase in free transfer RNA,
thus activating the GCN2 stress-kinase pathway leading to T cell
anergy and cell cycle arrest (77). On the other hand, a lack of
the amino acid leads to the inhibition of the rapamycin (mTOR)
pathway followed by a translational block (78). Moreover, via
the formation of different immunologically active kynurenine
metabolites, IDO also contributes to the apoptosis of effector T
cells and promotes the formation of regulatory T cells (59, 79).
Another important link between KP and the immune system
is manifested by DCs, in particular in their role in inflammatory
processes. Sepsis is a systemic inflammatory response syndrome
which leads to hemodynamic shock accompanied by multi-organ
failure. It is a major cause of mortality and morbidity among
hospitalized patients. Sepsis is the consequence of microbial
infection, in which Gram-negative bacteria outer-membrane
components (LPS) trigger the uncontrolled production of
pro-inflammatory cytokines, which leads to the imbalance of
pro-and anti-inflammatory factors. DCs seem to play a cardinal
role is sepsis development, as they are capable of producing pro-
(IL-12) and anti-inflammatory (IL-10) cytokines, the balance of
which was found to be altered during infection (80). In DCs,
IDO expression is induced by LPS and the enzyme production
contributes to the imbalance of anti- and pro-inflammatory
cytokines (2).
A growing body of data shows the involvement of IDO in
immune responses to tumors [see in (45, 46, 81)]. A pivotal role
of the enzyme is seen in establishing the immunosuppressive
microenvironment of tumors by altering the functions of
infiltrating T lymphocytes, thus promoting immune escape and
progression of cancer cells (82, 83). Upregulated expression of
IDO has been reported in the microenvironment of laryngeal
and esophageal carcinomas (84–87) and higher plasma enzyme
activity was reported in lung-, gynecological-, breast- and
colorectal cancers, and melanoma. Both local expression changes
and elevated plasma IDO activity was reported in patients
with nasopharyngeal carcinoma (NPC) (81). Interestingly, a
significant difference in plasma IDO levels could be detected
between healthy controls and NPC patients with metastasis, in
contrast to patients without metastasis. Plasma IDO activity
was also found to have a prognostic value, as patients with
higher levels of enzyme activity had significantly lower rates
of survival compared to those with lower IDO activity. Higher
enzyme activity was shown to result from higher expression
levels: Fukuno et al. reported that IDO mRNA expression in
patients with acute myeloid leukemia (AML) was associated
with a worse disease outcome (88). In light of the role IDO
plays in immune responses to cancer, it is no wonder that IDO
modulation is a hot topic in cancer research. Many therapeutic
approaches are underway for pharmaceutical enzyme inhibition
(65). This review will not discuss these in detail since our aim is
to give an overview of findings on approaches targeting the KP
by gene modulation.
Tryptophan-Dioxygenase
The first step of the KP can also be catalyzed by TDO, a functional
ortholog enzyme of IDO. However, while IDO is mainly
expressed by various immune cells, thus regulating the amount
of locally available Trp, TDO is expressed in the liver, affecting
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FIGURE 1 | The kynurenine pathway of tryptophan metabolism. Enzymes of
the KP metabolise Trp into products possessing immune- and
neuromodulatory properties. By the utilization of Trp and generation of NAD
coenzyme precursor the KP has profound effects on cellular protein and
energy metabolism. Several internal metabolites of the pathway play role on
redox regulation and have neuroprotective - or neurotoxic effects. Immune
functions are modified by the KP both directly, via immuno modulatory
metabolites and indirectly, via changing the metabolism of immune cells by
altering amino acid availability, redox status and energy balance.
Abbreviations: Trp: tryptophan; TDO:tryptophan 2,3-dioxygenase;
IDO:indoleamine 2,3-dioxygenase; N-formyl KYN:N-formyl-kynurenine;
L-KYN:L-kynurenine; KAT:kynurenine aminotransferase; KYNA: kynurenic acid;
KYNU:kynureninase; AA:anthranilic acid; KMO:kynurenine 3-monooxygenase;
3-HK:3-hydroxy kynurenine; XA: xanthurenic acid; KYNU:kynureninase;
3-HAA: 3-hydroxyanthranilic acid; 3-HAO:3-hydroxyanthranilate
3,4-dioxygenase; ACMS: 2-amino-3-carboxymuconate-semialdehyde;
ACMSD: aminocarboxymuconate-semialdehyde-decarboxylase; PIC: picolinic
acid; QUIN: quinolinic acid; QPRTase:quinolinate phosphoribosyltransferase;
NAD+: nicotinamide adenine dinucleotide; CNS: central nervous system.
the systemic level of the amino acid. The activity of the enzyme
can be regulated by various mechanisms. TDO transcription is
enhanced by glucocorticoids and this is potentiated by glucagon,
but inhibited by adrenaline and insulin (89). TDO can also be
activated by its cofactor, heme, and its substrate, Trp [reviewed
in (61)]. Recent evidence demonstrates TDO presence in rat
skin and the CNS of humans (90, 91), thus broadening the
location and raising further questions on the exact role of the
enzyme. As Trp stabilizes the TDO enzyme complex (92), and
cortisone, a hormone with anti-inflammatory effects, enhances
TDO expression (93, 94), one can expect the involvement of
the enzyme in immune processes. This was reported first in the
early 2000s (95, 96): in 2000, Tatsumi et al. proposed a role for
the enzyme in tolerance during embryonic implantation, based
on finding upregulated expression of TDO mRNA in murine
decidualized stromal cells surrounding the implanted embryo
(96). In 2001 Suzuki et al. reported high TDO expression during
early murine gestation, preceding the expression of IDO, thus
revealing an important role of TDO in fetal tolerance (95). When
regarding the immune modulator effects of the KP, research has
been mainly focused on IDO, but a growing body of evidence
is accumulating on the involvement of TDO as well. It indicates
the presence of the enzyme in tumor immune resistance (38,
97) and parasite, viral and microbial infections (98) (Table 5).
Expression of TDO by several different tumor types—such as
melanomas, bladder-, and hepatocarcinomas—drew attention
to the possible role of the enzyme in tumor immunity. TDO
was found to be constitutively expressed in glioblastomas and
excessive production of the AHR agonist KYN was found to
contribute to the immune escape, higher motility and survival of
tumor cells (38).
Kynurenine Monooxygenase
A third enzyme with assumed immunomodulatory effects of the
KP is KMO, which is situated at an important branch point
of the pathway. KYN can be catalyzed by KATs into KYNA,
representing a neuroprotective and antioxidant branch of the
pathway. On the other hand, KMO can convert KYN to 3-
HK, which can be further converted into PIC and QUIN. Both
of these metabolites are known to have neurotoxic and free
radical generating properties. Thus, KMO has a key role in
determining the balance between pro- (QUIN, 3-HK, PIC) and
anti-inflammatory (KYNA) kynurenine metabolites.
The substrate of the KMO enzyme, KYN, was shown to
promote tumor formation and the generation of regulatory
T cells via AHR (99) and adenylate- and guanylate-cyclase
pathway activation (38). However, the mode of action of KYN
on AHR raised questions, as the structure of the metabolite
does not show the necessary features for high-affinity AHR
binding. Recently two KYN condensation products have been
identified, which are high affinity AHR ligands, active at low
picomolar levels. Thus, KYN seems to be a pro-ligand that
spontaneously converts to derivatives possessing AHR agonist
properties (100). Theoretically, enhancing the metabolism of
KYN via KMO upregulation could be protective against the
development of tumors. However, upregulation of KMO also
leads to the formation of metabolites with reactive oxygen species
(ROS) generating properties, such as 3-HK, 3-HAA, and QUIN.
QUIN also exerts excitotoxic effects through the activation of
NMDARs (38). Pharmacological inhibition of KMO enhances the
production of KYNA, a metabolite with neuroprotective effects.
Besides its neuroprotective effects (101, 102) KYNA also has an
important role in immunomodulation, mainly via the activation
of GPR35 receptors and AHRs [reviewed: (103)]. KYNA was
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FIGURE 2 | Overview of pathways leading to IDO enzyme production and regulation. IDO activity is regulated at different levels. Its substrate Trp and cofactor heme
are positive regulators of the enzyme, whereas antioxidants and NO act as inhibitors. Phosphorylation at tyrosine side chains and ubiquitination modulate IDO activity
and half life. At the level of transcription several cis regulatory elements of the IDO promoter collect regulatory signals via binding of transcription factors and epigenetic
regulators, which respond to signals arriving from receptors that are activated by cytokines and other immunomodulatory molecules. Extracellular signals produced by
other cells or pathogens and intracellular signals, such as cytosolic dsDNA can both induce IDO expression and feed-back regulation of the production has also been
described [see text for details and (60)]. Abbreviations: IFN: interferon; TNF: tumor necrosis factor; TGFβ: transforming growth factor beta; LPS: lipopolysaccharide;
dsDNA: double strand DNA; TLR: toll-like receptor; TGFBR: transforming growth factor beta receptor; IFNBR: interferon beta receptor; IFNGR: interferon gamma
receptor; TNFR: tumor necrosis factor receptor; AHR: aryl hydrocarbon receptor; ISRE: IFN stimulated response element; DRE: dendritic cell response element; GAS:
gamma-activated sequences; HDAC: histone deacetylase; ∼P: phosphorylation; IDO: indoleamine 2,3-dioxygenase; SOCS3: suppressor of cytokine signaling 3; Trp:
tryptophan; NO: nitrogen oxide.
found to attenuate inflammation under inflammatory conditions
by several means: by reducing TNF expression inmonocytes, IL-4
secretion of T-cell receptor stimulated variant natural killer-like T
cells and LPS induced IL-23 formation of DCs [reviewed: (103)].
The expression of KMO was also found to be upregulated in
the CNS of rats in LPS induced systemic inflammation, together
with a significant increase in pro-inflammatory cytokines such as
TNFα and IL-6 (73).
KMO expression and activity have been investigated in
autoimmunity related diseases. A link seems to exist through
AHRs as these receptors play an important role in the regulation
of pro-inflammatory Th17 cell differentiation (42) and Trp
metabolites act as agonists of AHRs. KP metabolites play roles in
promoting the differentiation of naive T cells into effector Th17
cells (104), which are governors of autoimmune diseases (105).
Stephens et al. reported that Th17 cells highly express KMO, and
that either the inhibition of the enzyme or the addition of 3-HK
augmented the formation of effector T cells (42).
Since these three enzymes of the KP seem to be associated
with immune functions, genetic approaches aimed at modifying
immune responses are focused on altering their expression. So
far, primarily gene knockouts, gene expression regulation by
small interfering RNA (siRNA), short hairpin RNA (shRNA)
and different gene delivery techniques into model animals
and tissue culture cells have yielded results regarding the
immunomodulatory effects of these enzymes. The next section
will review these results. We find it important to point out here
that with the rapid progress of gene modulatory and gene editing
techniques it is expected that the data summarized here will grow
in the near future.
IMMUNOMODULATION VIA ALTERING THE
EXPRESSION OF GENES THAT CODE FOR
ENZYMES OF THE KYNURENINE
PATHWAY
Indoleamine 2,3-Dioxygenase
Effects of Genetic Modification of Indoleamine
2,3-Dioxygenase Related to Immune Responses in
Infection
During the course of sepsis, induction of IDO by bacterial
endotoxins plays a pivotal role in the disproportional production
of pro- and anti-inflammatory cytokines. Consequently, the
detrimental effects of excessive pro-inflammatory stimuli could
be lessened by the genetic inhibition of IDO (2). Indeed, in IDO
Frontiers in Immunology | www.frontiersin.org 9 November 2019 | Volume 10 | Article 2570
Boros and Vécsei Immunomodulatory Effects of the KP
FIGURE 3 | Effects on IDO activity on immune responses. IDO is expressed by
various cells of the immune system in response to activation by inflammatory
markers such as IFNs, ILs, TNFs, PGs and LPS. By decreasing the amount of
available Trp IDO activates the GCN2 stress-kinase pathway leading to T cell
anergy and cell cycle arrest, inhibits the mTOR pathway thus diminishing T cell
proliferation. By increasing KP metabolite concentrations IDO also contributes
to the apoptosis of effector T cells and promotes the formation of T cells of the
regulatory subtype. Via these mechanisms IDO might exert profound effects on
both systemic and local immune responses. Abbreviations: IFNs: interferons;
Ils: interleukins; TNFs: tumor necrosis factors; PGs: prostaglandines; LPS:
lipopolysaccharide; DC: dendritic cell; IDO: indoleamine 2,3-dioxygenase; Trp:
tryptophan; KP: kynurenine pathway; mTOR: mammalian target of rapamycin.
knockout mice (IDO−/−) the balance was shifted toward the
production of the anti-inflammatory IL-10. IDO inhibition had
beneficial effects on the survival rates as well: overall survival
from LPS induced shock was higher among IDO−/− animals
compared to wild-type mice (2) (Table 1).
In mouse model, Blumenthal et al. found upregulation of
IDO expression uponMycobacterium tuberculosis infection both
in vitro and in vivo. Though in vitro experiments indicated
that genetic ablation of the enzyme resulted in enhanced T cell
proliferation after infection, such changes were not observed in
vivo, as there was no significant difference between the numbers
of activated T cells in the lungs and lymph nodes of IDO−/−
and IDO+/+ animals. In accordance with this, the survival rate
of Mycobacterium tuberculosis infected IDO−/− mice did not
differ significantly from that of their IDO expressing counterparts
(8). Uropathogenic Escherichia coli (UPEC) was also found to
elevate IDO expression in vitro in human uroepithelial cells and
polymorphonuclear leukocytes. In mice in vivo genetic ablation
of the enzyme (IDO−/−) resulted in increased levels of pro-
inflammatory cytokines, such as granulocyte-colony stimulating
factor, IL-6 and IL-17, leading to an increase in granulocyte
accumulation and local inflammation in the bladder of animals
and decreased survival of extracellular bacteria as compared
to wild type (IDO+/+) mice. These observations led to the
conclusion that via IDO up-regulation the pathogen reduces
host inflammatory responses thus enabling its own survival (9).
Similarly to UPEC, infection with Rhodococcus equi, a facultative
intracellular pathogenic bacterium also enhanced IDO expression
in DCs and alveolar macrophages. In the liver tissue of IDO−/−
animals, infection with the pathogen decreased TGFβ level and
FOXP3 expression, indicating a reduction in T regulatory cell
responses, in parallel with prolonged liver inflammation (10).
The IDO immunomodulatory role was also studied in
chronic viral diseases. Infection of mice by LP-BM5 Murine
Leukemia Virus (MuLV) resulted in the development of fatal
immunodeficiency syndrome, also known as murine AIDS.
Similarly to acquired immunodeficiency in humans, murine
AIDS is characterized by activation and proliferation of T and B
cells with altered functions, a decrease in the number of function
of natural killer (NK) cells and abnormal cytokine production.
Animals suffering from the disease are more prone to developing
B cell lymphoma and to opportunistic infections. Genetic
inhibition of IDO was found to evoke protective effects in MuLV
infected animals: in IDO−/− mice an increase was observed
in the levels of type I IFNs and the number of plasmocytoid
dendritic cells (premature type of DCs, pDCs) accompanied by
a decrease in virus replication as compared to wild type animals.
Interestingly, type I IFN neutralization in IDO deficient animals
abolished the decrease in virus replication, suggesting a cardinal
role of these IFNs in immune responses against viruses (3). The
enhanced production of type I IFNs was attributed to pDCs,
which were earlier reported to produce a number of different
type I IFNs upon viral infection (106), and are chronically up
regulated in HIV patients too (107). According to a further report
from the same laboratory, genetic inhibition of IDO expression
was also beneficial with the encephalomyocarditis virus (ECMV)
murine model of acute viral myocarditis (4). Similarly to the case
of MuLV infected mice, IDO−/− animals showed a significantly
higher survival rate after ECMV infection compared to WT
mice. In knockout animals, ECMV replication was inhibited,
as demonstrated by the lower levels of viral genomic RNA in
the heart and consequently the decreased levels of myocardial
damage. The mechanism of the protective effect in the absence
of the enzyme is believed to be the lack of KYN and 3-HK
production. These metabolites are proposed to decrease the
production of antiviral type I IFNs, key factors in myocardial
damage protection. Indeed, treatment of IDO−/−animals with
these KP metabolites decreased the otherwise elevated levels of
type I IFNs and led to increased myocardial destruction and a
prominent reduction in the survival rate. Based on the findings
that bone marrow transplantation from IDO−/− animals to
IDO+/+ mice resulted in significantly higher IFNβ levels than
was in the case with IDO−/− animals receiving bone marrow
from WT animals, it was proposed that type I IFN production is
regulated in the bone marrow. It was concluded that inhibition
of antiviral type I IFN production by IDO is the result of
multiple mechanisms: on the one hand, the number of activated
macrophages is suppressed by the formation of KP metabolites,
and on the other hand, local Trp depletion also can contribute
to a decrease in type I IFN production (4). In pDCs type I IFN
production is regulated by the mTOR pathway (108) that can
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be antagonized by amino acid starvation (109). Considering that
IDO catalyses the metabolism of Trp, one can suppose that the
enzyme inhibits mTOR signaling via locally depleting Trp (4).
IDO overexpression was also found to be beneficial in the
course of West Nile virus infections. Using IDO expressing
HeLa cells, it was shown that overexpressing IDO prior to viral
infection resulted in a significant decrease in viral replication.
Excessive enzyme expression restricted the spread of the infection
to the neighboring cells (6).
In contrast with the findings of Hoshi and colleagues,
O’Connor et al. reported that IDO deficient LP-BM5 infected
mice displayed similar disease severity to their IDO expressing
counterparts. These authors detected no differences in retroviral
load between IDO−/− and WT animals, thus the lack of enzyme
did not seem to affect viral replication or viral spread (7).
Similar results were reported by Huang et al., as they found no
significant effect of either pharmacological or genetic inhibition
of IDO on the outcome and severity of MuLV infection. On the
other hand, this study identified IDO as a major factor in pain
hypersensitivity related to acute influenza A andMuLV infection.
IDO was found to enhance hypersensitivity via the production of
KYN, and genetic inhibition of IDO resulted in the alleviation of
acute and chronic pain related to infection (5).
Effects of Genetic Modification of Indoleamine
2,3-Dioxygenase on Immune Responses in
Autoimmune and Allergic Diseases
Besides inflammation related to bacterial and viral infections,
the role of IDO in autoimmune and allergic processes has also
gained attention (Table 2). Studies on the role of IDO in mucosal
allergic processes revealed that though the enzyme is not essential
for antigen-induced airway immune tolerance, it plays a cardinal
role in antigen-induced Th2 mediated immune responses (11).
Genetic inhibition of the enzyme in a mouse model of acute
allergic airway inflammation led to a decrease in effector T cell
formation and in the production of Th2 cytokines, such as IL-
4, IL-5, IL-9, and IL-13, which play important roles in asthma
and other allergic diseases (110). As a consequence, attenuation
in airway inflammation, mucus secretion, airway eosinophilia
and hyperresponsiveness was observed in IDO−/− animals when
compared to their WT counterparts. Investigation of a chronic
asthma model yielded similar results with fewer DCs in the
lymph nodes and a decrease in parameters indicating allergic
airway inflammation. In accordance with this, IFNγ (a Th1 type
cytokine) expression was elevated. In summary, IDO expression
of infiltrating DCs seems to be essential in promoting Th2 type
immune response upon exposure to airway allergens (11).
In contrast with the above, no effect of knocking out
IDO was found in an auto-inflammatory disease, systemic
juvenile idiopathic arthritis (sJIA) (12). In a number of sJIA
cases secondary hemophagocytic-lymphohistiocytosis (sHLH)
develops, a condition characterized by the over-activation of
macrophages [macrophage activation syndrome (MAS)], thus
leading to a potentially fatal disease state. The development of
a cytokine storm—in which IL-1β, IL-6, and IL-18 play cardinal
roles—is characteristic of both sJIA and sHLH (111). It has been
supposed that both sJIA and sHLH were the consequences of
the lack of effective down regulation of an exaggerated immune
response (112, 113). Taking into account the immunomodulatory
effects of IDO, assuming the involvement of the enzyme in
these disease states seemed well-grounded. However, results of
Put et al. did not support this hypothesis. Genetic inhibition of
IDO in mice models of sJIA, MAS, and sHLH, did not indicate
differences in the symptoms of IDO−/− animals as compared to
WT mice. Though neither the level of IDO2 nor TDO was found
to be elevated, they hypothesized that the absence of IDO was
compensated by other Trp metabolizing enzymes of the KP (12).
According to results reported by Lemos et al., the presence of
IDO is essential in provoking beneficial immune responses in a
mouse model of experimental autoimmune encephalitis (EAE)
(13). Cytosolic DNA leads to the activation of the Stimulator
of Interferon Genes (STING) adaptor and results in the
induction of interferon type I (IFNαβ) production. Continuous
activation of STING provokes autoimmunity due to a failure
in immune tolerance. In an EAE mouse model of multiple
sclerosis (MS), it was found that following immunization
with myelin oligodendrocyte glycoprotein (MOG), systemic
treatment with DNA nanoparticles (DNPs) or cyclic diguanylate
monophosphate (c-diGMP) induced STING signaling. In this
way, potent regulatory immune responses could be achieved
leading to restrained EAE severity and delayed disease onset. In
accordance with this, reduced levels of effector T cell infiltration
in the CNS and decreased immune responses to the administered
MOG therapy in the spleen were observed. Interestingly, MOG
treatment stimulated CNS neurons to express IDO, however,
after DNP therapy no IDO expression could be detected in
the CNS of immunized mice. The authors concluded that
while immunization with MOG led to IDO expression in
neurons, DNP induced the enzyme in tissues outside the CNS
and paradoxically diminished MOG induced IDO expression
in neurons. Based on these findings it was proposed that
IDO induction in lymphoid tissues inhibited infiltration of
effector immune cells in the CNS and consecutive neuronal
IDO expression. In accordance with the above, for therapeutic
responses IDO gene function was essential only in hematopoietic
cells and lack of IDO in non-hematopoietic cells did not cause
changes in the outcome of DNP therapy. The changes provoked
by DNP administration were found to be highly dependent on
intact IDO and IFNαβ receptor genes, as no therapeutic responses
were observed in either STING-KO or IDO−/− animals. It
was concluded, that attenuation of immune responses upon
DNPs and c-diGMP application was due to the induction of T
cell regulatory responses via the STING-IFNαβ-IDO pathway.
This, accompanied by elevated Trp degradation and changes
in the balance of pro-and anti-inflammatory metabolites and
cytokines, results in better immune response outcome (13).
Earlier reports on diminished Treg responses, exacerbated EAE
disease severity and increased encephalitogenic Th1 and Th17
responses in IDO−/− mice supports this notion. Administration
of the Trp metabolite 3-HAA, besides inhibiting Th1 and
Th17 cells, also enhanced Treg cell responses, thus improving
disease outcome. It was concluded that IDO, by promoting
the formation of Trp metabolites, such as 3-HAA, enhances
Treg differentiation (14).
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Investigation of IDO mRNA expression in mice with collagen
induced arthritis (CIA), an animal model of rheumatoid
arthritis (RA), revealed a significant increase in the level of the
transcript in the lymph nodes of affected animals. Enhanced
IDO expression was mainly limited to DCs in lymph nodes. By
comparing disease progression in IDO deficient to WT mice, it
was found that though the severity of the disease was similar
at the early stages, in WT animals a plateau was observed
5 days after disease onset, while in IDO−/− mice arthritis
progressed further leading to a more severe disease. Increased
joint damage, higher production of IFNγ and IL-17 in the lymph
nodes and higher Th1 and Th17 cell frequency were observed
in paws of IDO deficient animals. These observations led to
the conclusion that IDO activation in lymph nodes is essential
in reducing the accumulation of Th1 and Th17 cells in joints
and thus restraining disease severity and progression in RA
animal model (15).
In accordance with the findings of Criado et al., Chen et al.
reported that adenoviral vector-mediated intra-articular IDO
gene delivery (AdIDO) into ankles of CIA rats ameliorated
disease severity. In the ankle joints of CIA animals, a significant
reduction was observed in bone destruction, soft tissue swelling
and synovial hyperplasia. Furthermore, a significant decrease in
CD4+ T cell infiltration accompanied by a higher apoptosis
rate and reduced CD68 macrophage infiltration was detected
in AdIDO treated CIA animals. Reduced Th17 cell activity
was found as well, as was indicated by diminished IL-17,
IL-6, IL-1β concentrations and RORγt expression in ankle
joints and draining lymph nodes. The authors concluded
that IDO gene therapy reduced arthritis via the up-regulation
of the Trp degradation pathway, thus increasing kynurenine
concentrations, leading to increased CD4+ T cell apoptosis and
diminished IL-17 production (16).
Type I diabetes is an autoimmune diseases, in which
insulin-producing pancreatic cells are destroyed by activated T
lymphoctyes (114). In pDCs IDO expression is triggered by
TGFβ via the non-canonical NF-κB pathway. Besides its Trp
catabolizing ability, in pDCs IDO acts as a signaling molecule as
well: promoting its own and also TGFβ expression, it amplifies
immune tolerance and enables the spreading of TGFβ dependent
tolerance (115–117).
In a study of non-obese diabetic (NOD) mice, the animal
model of autoimmune diabetes, TGFβ failed to activate the
non-canonical NF-κB pathway, thus no up-regulation could
be achieved in Ido expression. However, after transfection of
the Ido gene into NOD pDCs, TGFβ administration led to
the activation of the NF-κB pathway. This enhanced IDO
expression was accompanied by a decrease in IL-6 and TNFα
pro-inflammatory cytokine production and an up-regulation
of the anti-inflammatory TGFβ, ensuring a more immune-
tolerant setting. Enhanced IDO expression also led to decreased
production of pancreatic β-cell auto-antigens. It was concluded,
that immunoregulatory functions of TGFβ require a basal
expression level of IDO, which could be achieved by the
forced expression of the enzyme (17). The observation that
enhancement of both the enzymatic and signaling activity of IDO
proved to be beneficial in NOD mouse model, might allow us
to expect success from IDO modulation in other, autoimmune
diabetes related disorder as well.
A study reported by Ravishankar et al. further strengthens
the role of IDO in the course of autoimmune diseases. In a
model of Lupus-prone Murphy Roths large (MRLlpr/lpr) mice—
an analog of systemic lupus erythematosus (SLE)—significant
constitutive IDO expression was observed in the spleen of pre-
symptomatic MRLlpr/lpr animals. In contrast, in normal mice
little basal IDO activity was present. Treatment of MRLlpr/lpr
mice with pharmacological IDO inhibitor, D1MT, yielded
significantly elevated autoantibody levels and IgG immune-
complex deposition in the skin and kidneys of affected animals,
what is a manifestation of loss of self-tolerance. Injecting
apoptotic thymocytes in IDO−/− MRLlpr/lpr animals resulted
in an increase in autoantibody titers, pro-inflammatory cytokine
production, and dysregulated T cell responses culminating in
lethal autoimmunity. On the other hand, exposure of IDO+/+
MRLlpr/lpr mice to apoptotic cells did not lead to pathogenic
autoimmunity, as the response to thymocytes was low and self-
limiting.Whether the presence of IDO enables the suppression of
T cell responses to the antigens presented or whether it inhibits
the antigen presentation itself to potentially autoreactive T cells,
needs further elucidation. Nevertheless, the role of IDO in the
maintenance of immune homeostasis and in the prevention of
autoimmune progression is inevitable (18).
Effects of Genetic Modification of Indoleamine
2,3-Dioxygenase on Transplant Related Immune
Responses
Besides studies on the role of IDO in immune responses
to infections and autoimmune reactions, its involvement in
transplant responses is also a focus of research (Table 3). A
possible way of treating autoimmune (Type I) diabetes could
be the restoration of insulin production via the transplantation
of insulin producing pancreas cells (118). However, major
concerns are the reappearance of autoimmunity and the rejection
of the allograft (119). A study by Alexander et al. yielded
promising results with respect of these issues. They found that
transplantation of diabetic mice with pancreatic islets expressing
IDO via adenoviral gene transfer resulted in prolonged graft
survival (19). In vitro experiments revealed a significant depletion
of locally available Trp and inhibition of the proliferation of T
cells obtained from diabetic animals. The extended in vivo graft
survival was proposed to be due to local Trp depletion at the
site of transplantation, in accordance with the in vitro findings.
These results suggest that transplanted pancreatic cells expressing
IDO due to ex vivo genetic editing are capable of inhibiting
the proliferation of host diabetic T cells, thus preventing graft
rejection (19). These findings open new possible avenues in the
treatment of type I diabetes.
Enhanced IDO expression was also found to be beneficial
in the case of transplantation of an immune-privileged tissue,
the cornea (20). Over expression of IDO in donor corneal
endothelial cells prior to the transplant resulted in increased
formation of L-KYN in the allograft. As a consequence, the
proliferation of allogeneic T cells was locally inhibited, thus
permitting the prolonged survival of the graft when compared to
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no IDO expresser controls. Similarly, enhanced IDO expression
prevented lung allograft injury in a rat model. Liu et al.
used non-viral gene transfer methods to deliver human IDO
gene to enhance IDO expression in the transplanted lungs.
They found that both functional and histological properties
of IDO overexpressing lungs were significantly improved in
comparison to allografts without enhanced gene expression (21,
23). IDO gene delivery blocked local T cell responses, but
could not prevent the recruitment of neutrophil granulocytes.
Enhanced IDO expression led to the inhibition of intracellular
ROS formation, thus reducing ROS induced necrosis and
apoptosis of lung cells (21). IDO overexpressing lung allografts
displayed more preserved bronchus-alveolar architecture due
to significantly less interstitial and peribronchial collagen
deposition than controls. In vitro IDO expressing lung cells
inhibited the TGFβ mediated proliferation of fibroblasts,
however, this could also be prevented by the addition of
Trp, suggesting that local Trp depletion due to enhanced
IDO expression was the mechanism of fibroblast proliferation
prevention (23).
In following studies, Liu et al. found that in transplanted lung
allografts IDO overexpression reduced the number of infiltrating
CD3+ and CD8+ T cells. CD8+ T cells lost their cytotoxic
properties, and a significant reduction was observed in their
TNFα and IL-2 production. In vivo findings revealed that IDO
overexpression limited ATP production in CD8+ cells. In vitro
studies showed that IDO selectively diminished the activity of
electron transport chain complex I, which explains the reduced
ATP production of infiltrating T cells (22).
Further studies revealed that besides enhanced IDO
expression, systemic administration of a KP metabolite, 3-
HAA was also capable of prolonging lung allograft survival.
Furthermore, IDO overexpression in lung allografts, in addition
to TNFα and IL-2, also decreased the level of IFNγ, IL-12, IL-4,
IL-5, IL-6, and IL-13. However, there was no reduction in the
level of a potential protective cytokine, IL-10. As IL-2, IL-4,
IL-12, and IL-6 play important roles in the production of effector
memory T cells, it was proposed that IDO overexpression
inhibited not only early T cell responses, but also diminished
the formation of memory T cells, thus prolonging the survival
of the allograft. In vitro findings demonstrated that high IDO
environment led to decreases in intracellular calcium levels,
phospholipase C-γ1 phosphorylation and mitochondrial mass.
These observations offer novel insight into the mechanisms
by which IDO exerts T-cell inhibiting properties: namely by
impairing T cell receptor activation via decreasing calcium
influx, thus impairing calcium signaling (26).
IDO overexpression in fibroblasts diminished CD3+ T cell
recruitment at cutaneous wounds as well. The in vitro model
showed that wounds receiving IDO expressing human fibroblasts
had faster healing rates compared to those grafted with non-
treated fibroblasts. This was partly because of the significantly
increased vascularisation in wounds prior to receiving IDO
expressing fibroblasts as observed in an in vivo rat model.
However, the addition of Trp diminished otherwise enhanced
angiogenesis, implicating the Trp depleting role of IDO in the
course of capillary formation (24).
Overexpression of the enzyme was found to be beneficial
regarding cardiac allograft survival as well. Overexpression of
IDO in DCs resulted in decreased allogeneic T cell proliferation
in vitro. Based on in vivo experiments it was concluded that
adenovirus mediated IDO gene transfer in the donor heart led
to decreased monocytes, macrophages and T cells infiltrating the
organ. This was accompanied by diminished intragraft IFNγ,
TNFα, TGFβ, and IL-1β levels and prolonged graft survival (25).
Altogether, these findings underline the feasibility of
using IDO gene induction for the purpose of preventing
allograft rejection.
Effects of Genetic Modification of Indoleamine
2,3-Dioxygenase on Immune Responses in Disease
States Related to Chronic Inflammation and in
Intestinal Immunity
In addition to its possible use to modulate immune processes
related to infectious diseases, allergy, transplantation, and
autoimmunity, the involvement of IDO has also been
investigated in diseases accompanied by chronic inflammation,
such as diabetes, aorta aneurysm, obesity, and hepatic fibrosis
(Table 4).
Hyperglycaemia induced chronic retinal inflammation has a
pivotal role in the development of diabetic retinopathy (DR), one
of the major causes of visual impairment worldwide (120). In
a recent study, Nahomi et al. reported a 50 percent increase of
the level of IFNγ in human diabetic retinas accompanied with
elevated IDO expression (27). Genetic inhibition of IDO function
in diabetic IDO−/− mice was found to reduce retinal capillary
degeneration, as acellular capillary formation in knockout mice
was alleviated as compared to their WT counterparts (27).
Chronic inflammation has been reported to be a primary
feature of atherosclerosis as well (121). The higher angiotensin
II (AngII) plasma levels in atherosclerosis suggest hormone
involvement in the development of various cardiovascular
diseases. This raised the possibility of using the hormone to
generate animal models of diseases linked to atherosclerosis.
Indeed, infusion of Apolipoprotein E knockout (ApoE−/−) mice
with AngII led to the development of more severe atherosclerotic
lesions in the aorta. In the affected aortic segments, high
numbers of lipid-laden macrophages and lymphocytes were
observed accompanied by increased macrophage infiltration
in the adventitia (122). In a mouse model of atherosclerosis,
AngII was found to enhance the expression of IDO in parallel
with increased IFNγ expression, indicating a link between the
KP and arterial degeneration (28). Inhibition of the enzyme
exerted beneficial effects, as in WT mice AngII infusion resulted
in increased oxidative stress, dysfunction, and apoptosis of
endothelial cells, however, these detrimental effects were all
suppressed in IDO−/− animals. AngII infusion also increased
plasma kynurenine levels in WT animals, however, such changes
were not observed in IDO deficient ones. In vitro studies revealed
that upon IFNγ induced Ido activation, 3-HK is formed, which,
by increasing nicotinamide adenine dinucleotide phosphate
(NAD(P)H) oxidase activity, leads to enhanced ROS production,
triggering dysfunction and apoptosis of endothelial cells (28).
These results propose a possible therapeutic approach to
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atherosclerosis linked cardiovascular diseases: genetic inhibition
of IDO leading to reduced 3-HK and, consequently, diminished
ROS production could be a feasible way of avoiding endothelial
cell loss.
Abdominal aortic aneurysm (AAA) is a potentially fatal
condition characterized by the abnormal dilatation of the
abdominal aorta. The pathomechanism leading to the disease is
similar to that seen in atherosclerosis, as it includes the apoptosis
of vascular smooth muscle cells (VSMCs), degeneration of the
extracellular matrix by ametalloproteinasemediatedmechanism,
collagen remodeling and chronic inflammation of the aortic wall
(123, 124). In a hypercholesterolemic mouse model of AAA,
in which low density lipoprotein—receptor deficient (Ldlr−/−)
mice were infused with AngII and fed with high fat diet (HFD),
the absence of IDO was found to be protective against the
development of aneurysms (29). In IDO−/− animals infused
with AngII, TUNEL assay did not indicate increased levels of
apoptosis, but α-actin staining was increased. Both observations
suggest the protective effect of IDO exerted via the inhibition of
apoptosis of VSMC. A comparison of circulating immune cells in
IDO+/+ and IDO−/− animals revealed no significant difference
in the number of neutrophils, monocytes, CD4+ and CD8+
T cells or CD19+ B cells. Similarly, no significant difference
was detected in infiltrating macrophages and T lymphocytes
in the adventitia and media of the aortic aneurysm. However,
IL-17 production was significantly decreased in IDO deficient
animals as compared to their IDO expressing counterparts (29).
In summary, these findings raise the possibility of a mechanism
similar that seen in the development of atherosclerosis. As such,
IDOmediated 3-HK formation could be one of the main culprits
in arterial wall degeneration (28, 29).
Recently a further kynurenine metabolite and an enzyme of
the pathway were identified to take part in the pathomechanism
of the disease. According to a study by Wang et al., IDO
knockout and siRNA mediated Kynu silencing in ApoE−/−
mice were protective against AgII induced AAA formation
(30). In ApoE−/− mice the genetic inhibition of both IDO
and KYNU caused a decrease in elastic lamina degradation
and aortic expansion was observed following AngII infusion.
The comparison of serum inflammatory markers, such as
IFNγ, TNFα, IL-6, and cyclophilin-A, revealed no significant
differences between IDO expressing and IDO−/− animals,
suggesting another IDO regulated mechanism apart from
immune mediation. 3-HAA was identified as a main factor
in the pathomechanism of aneurysm development as it was
found to upregulate the expression of matrix metallopeptidase 2
(MMP2), which has a central role in the pathophysiology of AAA
formation via extracellular matrix degeneration (30, 125).
The production of 3-HAA was regulated by both IDO and
KYNU. On the one hand, AngII infusion in IDO+/+ mice
induced the expression of both enzymes, which resulted in the
elevation of the level of 3-HAA both in the plasma and aorta
of these animals, however, no such changes were observed in
the absence of IDO. On the other hand, genetic inhibition of
KYNU led to decreased 3-HAA production and diminished
MMP2 expression, consequently preventing the formation of
AAA (30). The investigation of human AAA samples revealed
similar changes in the KP: both IDO and KYNU enzymes
were significantly upregulated in human aneurysm samples,
accompanied by higher levels of 3-HAA in the affected aortic
wall (30). These findings underline the therapeutic potential of
interfering in the pathway to prevent vascular degeneration.
Association between obesity, inflammation and the gut
microbiome has been intensively investigated in the past decades
(31, 126). In a recent study, Laurans et al. reported that IDO−/−
mice fed a high fat diet showed lower body weight and fat
mass compared to WT animals on the same diet. Knockout
animals also had lower liver weights accompanied by less lipid
accumulation and decreased macrophage infiltration in the
organ, implying the presence of a protective mechanism against
steatosis. A decrease in inflammatory processes was also detected
in white adipose tissue (WAT) of IDO−/− mice compared
to their wild type counterparts. In epididymal and inguinal
adipose tissues, lower numbers of infiltrating macrophages were
detected and in inguinal WAT the number of M2 type cells
was higher, whereas there was no significant change in the
number of M1 type cells (31). M2 macrophages are associated
with alleviating inflammation, propagating wound healing and
are regarded as a “benign” subtype in contrast with the pro-
inflammatory, activated M1 type ones (127). In accordance
with this, the levels of anti-inflammatory cytokines—such as
IL-10, 4, and 5—were significantly higher in animals lacking
the enzyme. Besides protection against liver steatosis, genetic
inhibition of IDO also proved to be beneficial against the
development of insulin resistance, as indicated by lower insulin
concentrations measured during oral glucose tolerance tests
(OGTT) and better results to insulin tolerance tests (ITT) by
IDO−/− animals compared to WT mice. These findings suggest
the protective role of IDO inhibition against obesity and obesity
related pathological changes in metabolism affecting the liver and
glucose homeostasis. Laurans et al. also attempted to identify
the causative role of IDO in obesity and related disorders. They
found that KYN and KYNA supplementation did not abolish
the positive effects of IDO deletion on body weight, thus it is
unlikely that the beneficial metabolic changes seen in the case
of IDO inhibition are the consequences of the lack of these
metabolites (31). Several previous observations on obesity related
intestinal dysbiosis and gut derived LPS translocation (128), the
demonstration of high IDO expression in the gastrointestinal
tract, and that activity of IDO was increased in the intestine of
high fat diet animals (129) support the assumption that higher
intestinal IDO expression leads to a shift toward kynurenine
production instead of the formation of indole derivatives (31).
In concert with this assumption, Laurans and colleagues found
that in the IDO−/− HFD fed mice higher intestinal levels of
indole-3 acetic acid (IAA) were present. In parallel with this,
the levels of two cytokines known to be dependent on indole
derivatives (130), IL-17 and IL-22 [which both play primary
roles in rapid immune response of the host against microbes
(131)] were increased, accompanied by the decreased expression
of inflammation related genes. These changes in the intestinal
tract were accompanied by significantly diminished LPS levels in
the plasma of IDO−/− animals on HFD compared to WT HFD
animals. All combined, these findings strongly suggest a causative
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effect of IDO deletion in maintaining an intact intestinal immune
barrier in obesity (31).
However, while the absence of IDO can be beneficial, as in
most of the cases cited above, the lack of the enzyme can also
have detrimental effects in certain cases. The seemingly opposing
findings demonstrate the diverse and complex role of the enzyme
in the regulation of immune processes. Hepatic fibrosis is a
consequence of chronic inflammation which can be triggered
by various agents, such as viral infection, drugs, metabolic and
autoimmune diseases (32). Elevated expression of IDO has been
reported in hepatitis (132), leading to the assumption that the
enzyme might be involved in hepatic fibrosis. Based on data
of elevated levels of pro-inflammatory cytokines, such as TNFα
and IL-6, in a hepatitis model, Ogiso et al. proposed that the
induction of IDO by pro-inflammatory agents might play a role
in the disease. In a carbon-tetrachloride (CCl4) induced animal
model of the disease, the absence of IDO was found to aggravate
the progress of fibrosis. The number of macrophages producing
TNFα was significantly higher in the liver of IDO knockout
animals, leading to a rise in the level of TNFα accompanied
by the elevated expression of fibrogenic factors as compared to
WT animals. On the grounds that IDO activation leads to a
decrease in available Trp with the simultaneous production of
kynurenine metabolites and that Trp is cardinal in the activation
of NK and T cells, it was proposed that the elimination of IDO
activity contributes to liver fibrosis by a dual mechanism: the
inhibition of the enzyme results in sufficiently high Trp levels for
lymphocyte activation and prevents the formation of kynurenine
metabolites that suppress lymphocytes (32).
IDO seems to play an important role in intestinal immunity
under normal circumstances as well. Harrington et al. reported
a significant elevation of IgA and IgG in the gut and sera of
IDO−/− mice as compared to wild type animals (33). Antibiotic
treatment of IDO−/− animals led to a decrease in IgA and
IgG levels indicating that the increased level of these Igs was
a consequence of the lack of IDO modulatory effects on gut
microbiota. Based on the observation that the elevated baseline
Ig levels of IDO null animals could be corrected by antibiotic
treatment, the authors proposed the involvement of IDO in
a negative-feedback mechanism, which limits B lymphocyte
responses to commensal microorganisms in the intestinal tract.
This notion was supported by the finding that infection of
IDO−/− mice with a bacterial enteropathogen similar to the
human pathogen Escherichia coli, Citrobacter rodentium, resulted
in attenuated intestinal inflammatory responses. This was
manifested in less oedema, cellular infiltration, epithelial damage
and reduced intestinal colonization of the bacteria in IDO null
animals as compared to WT (33). These beneficial effects were
attributed to the elevated formation of natural secretory IgA,
which facilitated the prevention of intestinal colocalization of the
pathogen. It was hypothesized that IDO regulated gut microbiota
by stimulating Ig production via the formation of cytotoxic
kynurenine metabolites, as these kynurenines could inhibit
the proliferation of the antibody producing B cells. Another
mechanism by which the enzyme can affect B cell responses is
by its ability to modulate T cell activity (33).
Effects of Genetic Modification of Indoleamine
2,3-Dioxygenase on Immune Responses to Cancer
A steadily growing body of data shows upregulated states of
IDO in various cancer types making it a potent target for
therapeutic approaches. To date, several chemical inhibitors of
the enzyme have reached clinical trials, however, there are only
a handful of those therapeutic approaches which attempt to
modulate the enzyme function by genetic means [reviewed in
(65)]. Besides post-translational modifications, the activity of
the enzyme is also controlled at the transcriptional level (65),
and in most interventions a decrease in the enzyme activity is
desired, so genetic modulation seems feasible and exploring ways
to achieve it is highly warranted. As upregulated IDO expression
has been reported in various tumors (81), silencing the IDO
gene could be an effective way for interfering immune escape
in malignancies (Table 4). Report that IDO silencing by siRNA
technology in cultured B16F10 melanoma cells diminished Trp
catabolism and prevented apoptosis of T cells supports this
notion. Transplantation of IDO inhibited tumor cells into mice
resulted in the formation of smaller tumors. Moreover, in vivo
IDO-siRNA treatment enabled the recovery of T cell responses,
thus restoring host antitumor immunity, and silencing the gene
also caused a delay in tumor onset (34). In melanoma mouse
model, silencing injection of IDO specific shRNA, expressed
from a plasmid in Salmonella typhimurium, attenuated tumor
growth and led to a significant decrease in the number of lung
metastases. In Ido-silenced animals massive tumor cell death was
observed accompanied by polymorph nuclear neutrophil (PMN)
infiltration in tumors. The production of excessive amounts of
ROS led to the apoptosis of cancerous cells. Though it is likely
that cytotoxic PMN recruitment is primarily to clear off S.t.
cells, the production of ROS generates a microenvironment that
is disadvantageous for tumor growth (35, 133). IDO silencing
has been demonstrated to be effective in ovarian cancer as well
(36). Injection of SKOV-3 human ovarian cancer cells with
short hairpin RNA (shRNA) silenced IDO (SKOV-3/shIDO)
into mice resulted in reduced tumor growth when compared
to animals receiving IDO expressing cells. Simultaneously,
peritoneal dissemination and ascites formation was inhibited and
NK cell accumulation in the tumors was increased in SKOV-
3/shIDO cell injected mice compared to those injected with
tumor cells without IDO inhibition. In vitro studies revealed
that in co-culture with NK cells, SKOV-3/shIDO cells displayed
significantly decreased survival rates compared to those of non-
IDO inhibited SKOV-3 cells, suggesting that IDO inhibition
increases cancer cell sensitivity to NK cells (36).
In a recent study Wang et al. reported that radiotherapy
(RT) treatment of patients with non-small cell lung carcinoma
caused a decrease in KYN/Trp ratio, indicating diminished
IDO activity, which was restored post-RT. They also reported
a significant correlation between IDO activity and the clinical
outcome of patients receiving RT. Those patients who had a
higher KYN/Trp ratio prior to RT treatment showed significantly
poorer survival than those with a lower KYN/Trp ratio. Similarly,
there was correlation between greater KYN levels pre- and post-
RT treatment and modest survival. These data suggested that
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RT induced favorable immune activity changes and IDO activity
depended on the dose of implemented RT therapy. The authors
hypothesized that defining the optimal dose of therapy is crucial
in the modulation of IDO function, as a low dose would not be
able to cause satisfactory immunomodulatory changes, whereas
overdose can lead to detrimental impairment of the immune
system (134).
The potential of enhancing cancer treatment efficacy by IDO
function modulation was also demonstrated by Vareki et al. Anti-
IDO shRNA transfected A549 human lung adenocarcinoma cells
exhibit enhanced sensitivity to anti-cancer treatment. Genetic
depletion of IDO sensitized the cells to the NAD+ inhibitor
FK866, base excision repair (BER) inhibitor methoxyamine
(MX), the folate anti-metabolite pemetrexed and the nucleoside
analog gemcitabine—the latter two are already approved
anticancer drugs. Simultaneous downregulation of IDO and
thymidylate synthase (TS), a rate-limiting and key enzyme of
DNA repair, led to the sensitization of the cells to 5FUdR
as well. These results demonstrate the potential of genetic
inhibition of IDO in combination with chemotherapy in cancer
treatment (37).
Thus far, IDO targeting in cancer research and in therapeutic
approaches involves mainly pharmaceutical enzyme inhibition.
However, the use of IDO inhibitors has limitations [reviewed in
(135)], underpinning the importance of genetic interventions,
both alone and in combination therapy. Most of the known
IDO inhibitors are analogs of the enzyme’s natural substrate and
act as competitive inhibitors of the enzyme. Thus, in order to
exert the desired effect, these molecules either need to be used
in concentrations at which they can compete with Trp in the
target site, or need to show higher affinity for the enzyme than
its own substrate. Trp analogs can also interfere with amino
acid supply, thus misleading the cell, which in turn cannot give
competent responses to changes in nutrient levels. A further
limitation is that several of the applied drugs, such as 1-MT,
Epacadostat, Norharmane, and Navoximod are AHR activators.
This calls for specific attention, since there are data on AHR
ligands possessing pro-carcinogenic effects [reviewed in (135)],
though results are conflicting in regard of this question and
further investigation is needed in order to clarify this issue.
On the other hand, it must be emphasized here that similarly
to the disadvantages and concerns regarding pharmaceutical
enzyme inhibition, genetic modifications also carry dangers and
raise several questions [reviewed in (136)]. There are concerns
regarding the use of both viral and non-viral vectors and the
off-target effects. Integration of the transfected genetic material
into unwanted sites might evoke unwanted, potentially fatal
immune responses for the host. While choosing sides between
the two therapeutic approaches at present is hardly possible,
in light of the progress of drug design and gene delivery
techniques, it is likely that IDO targeting in either way or
in combination will enter into the regiment of treatments of
important malignancies.
Tryptophan-Dioxygenase
Similarly to IDO, the effect of the functional ortholog enzyme,
TDO, expression was studied on the immune response to
tumors in animal models. Pilotte compared tumor rejection
rate observed upon injecting TDO expressing and TDO non-
expressing P815 tumor cells into the peritoneal cavity of mice
(38). Though both cell lines produced tumors, the growth of
tumors resulting from cells not expressing TDO was slower
than those originating from cells which expressed TDO. TDO
expression led to a decrease in T lymphocyte proliferation in
the tumor microenvironment, indicated by the fewer cytolytic
T lymphocytes (CTL) detected in the peritoneal cavity of
animals. They concluded that TDO inhibition promotes tumor
rejection. Furthermore, they concluded that inhibition of IDO
and TDO might have synergestic effects in improving host
response to tumors. Interestingly, pharmacological inhibition of
TDO potentiated tumor-rejecting ability (38). These findings
raise the possibility of targeting the TDO enzyme in an anti-
tumor therapy.
While inhibition of T lymphocytes resulting from TDO
expression can be detrimental for anti-tumor activity, the activity
of the enzyme can be beneficial in the fight against infectious
diseases. TDO expressing HeLa cells were found to exert
antiparasitic, antiviral and antibacterial effects, as these cells
were found to be able to inhibit the growth of Toxoplasma
gondii, Herpes simplex virus and Staphylococcus aureus after
tetracycline stimulation. Similarly to the finding of diminished
T lymphocyte proliferation in the tumor microenvironment
upon TDO expression, the presence of the enzyme resulted
in the restriction of T cell proliferation in cells pre-treated
with anti-CD3 mitogenic antibody. Furthermore, supernatant
obtained from TDO expressing cells was capable of inhibiting
allogeneic T cell responses. Both the antimicrobial and T cell
proliferation inhibitory effects of TDO expressing cells were
blocked by administering exogenous Trp, suggesting that the
mechanism by which these effects are achieved is due to the
decreased level of Trp available because of its metabolization
by TDO (40).
A recent study of Elbers et al. revealed that hypoxia
significantly impaired both antibacterial, antiparasitic and
immunoregulatory properties of TDO. Investigation of TDO
expression and enzymatic activity in HeLa cells engineered to
express the enzyme and murine liver homogenates revealed that
under low oxygen conditions, though the expression was not
affected, the enzymatic activity of the protein was significantly
reduced. In line with this, under hypoxic conditions, the growth
of Enterococcus faecalis and Staphylococcus aureus was no longer
inhibited, and T cell proliferation was restricted. Considering
that hypoxia can often be observed in tumoral tissues and
that infected tissues often exhibit low oxygen levels, the loss of
normoxia could be a key factor in the loss of appropriate immune
responses against pathogens and tumors (137).
Genetic inhibition of TDOwas also investigated in EAEmodel
of MS. Though TDO deficiency had no impact on leukocyte
infiltration in the CNS, nor on the rate of demyelination, disease
activity or degradation of the optic nerve, it had protective
effects against neuronal loss in the spinal cord. This discrepancy
could be explained either by the different sensitivities of these
areas and/or by the diverse expression of TDO in separate brain
areas (39).
Frontiers in Immunology | www.frontiersin.org 16 November 2019 | Volume 10 | Article 2570
Boros and Vécsei Immunomodulatory Effects of the KP
As TDO is expressed in the liver, and some corticoids
which are widely used in immunosuppressive therapy following
transplant induce its expression (93, 138), it follows that TDO
modulation might be exploited in allogeneic liver transplant
protection. Reduction of locally available Trp in the liver can
diminish T cell responses (40), while simultaneous production
of kynurenines can promote the development of suppressive,
rather than effector dendritic cells, thus further inhibiting T cell
responses (138). At present, however, there is no available data
on findings on the effects of the genetic modulation of TDO on
liver transplantation. Taking into account the reasons mentioned
above and the positive effects of IDO modulation on allograft
rejection, investigating the possibility of TDO use in this respect
seems warranted.
Kynurenine 3-Monooxygenase
The third enzyme of the KP which has been subject to studies
concerning its immunomodulatory roles is KMO. In light of
the position of KMO in the hierarchy of KP enzymes, and
that the induction of KMO is likely to shift the balance
toward the production of neurotoxic and pro-inflammatory
metabolites, targeting enzyme inhibition is a tempting approach
for interfering in excessive inflammatory processes. Indeed,
modulation of KYNA production by KMO inhibition has gained
interest in the past decades and is a promising therapeutic
approach for disease states linked to neurodegeneration, major
depression, cancer, and immunological abnormalities (139).
Besides utilizing specific KMO inhibitors,Kmo knockout animals
are also efficient tools for investigating the effects of the lack of the
enzyme (Table 5).
Giorgini et al. generated Kmo−/− mice and investigated
the levels of different KP metabolites in the brain, liver, and
plasma of the animals. The levels of Trp and NAD+ tended
to be only slightly decreased in these tissues. The marginal
decrease in Trp level suggests that KMO inhibition has only
a slight influence on upstream KP enzymes such as IDO and
TDO. The findings that practically no difference in NAD+
levels was found supports the assumption that alternative
NAD generating mechanisms are able to produce the necessary
amount of metabolite when the KP is inhibited. The levels
of KYN, AA, and KYNA were elevated, with a more striking
increase in the level of the latter in the periphery than in
the brain. Interestingly, though the levels of the product of
the enzyme, 3-HK, were significantly decreased both in the
periphery and the brain, the metabolite was still detectable. This
observation suggests that in KMO−/− animals other enzyme
isoform(s) are capable of producing the metabolite in small
quantities (139). Noteworthy was the difference between levels
of QUIN in the periphery and in the CNS of Kmo null
animals. A significant decrease in the level of this excitotoxic
metabolite was detected both in the liver and plasma of
KMO−/−animals, but there was only a moderate decrease
in the brain. Based on these findings the authors concluded
that peripheral inhibition of KMO might be sufficient for
neuroprotection, as targeted inhibition of KMO in the CNS
would not result in a more prominent decrease in the levels
of QUIN (139). Though the decrease in the amount of 3-
HK and QUIN accompanied by the increase of KYNA levels
in the CNS could shift neurotoxicity toward neuroprotection,
excessive elevation of KYNA holds plenty of danger (140).
There is a growing body of evidence on the association
of exaggerated KYNA levels and impairment in cognitive
functions (101, 141–143).
Genetic modulation of KMO activity as a possible therapeutic
approach for intervening infections was investigated by Kubo
et al. in an EMCV induced mice model of viral myocarditis
(41). They found that the survival rate of KMO−/− mice
was significantly higher compared to WT animals. This was
accompanied by a significant decrease in the cellular infiltration
of macrophages and neutrophils in the heart tissue of knockout
animals. Moreover, the number of EMCV infected cells was
significantly reduced in KMO−/− specimens in parallel with
lower levels of EMCV genomic RNA. Viral infection upregulated
the expression of Kmo as significantly higher Kmo mRNA
levels were detected in KMO+/+ animals after EMCV infection.
These findings support the notion that links upregulated enzyme
expression to higher mortality upon viral infection. Differences
between WT and knockout animals were detected not only
in the heart tissue but also in the periphery. In the serum
of KMO−/−mice lower chemokine and cytokine levels, while
higher levels of KYN and KYNA were detectable compared
to WT animals (41). KYN has been shown to inhibit T
and NK cell proliferation, and, via the generation of ROS,
induces the apoptosis of NK cells (144–146). KYNA also exerts
immune modulating effects by restricting TNF production of
macrophages via G protein-coupled receptor GPR35 activation
(147). Based on the anti-inflammatory effects of KYN and KYNA,
elevated levels of these metabolites are proposed to be key
factors in decreased inflammatory responses seen in KMO−/−
animals. Thus, genetic inhibition of the enzyme is expected
to exert beneficial effects by preventing excessive cytokine and
chemokine production and decreasing the recruitment of cells of
the immune system (41).
In a mouse model of autoimmune gastritis, siRNA mediated
gene silencing of Kmo led to the exacerbation of the disease.
A self-regulatory mechanism was proposed, whereby the
expression of Kmo ensures kynurenine catabolism, therefore
reducing the amount of available AHR agonist kynurenine, thus
lessening the formation of Th17 cells and pro-inflammatory IL-
17 production. Accordingly, the inhibition of the enzyme
exacerbated inflammatory processes via promoting the
formation of Th17 cells (42).
Changes in KMO function have been reported in diseases
linked to chronic inflammation as well. The expression of
KMO in podocytes was found to be decreased in a diabetic
environment, both in human and mouse kidneys (43). Genetic
inhibition of the enzyme under diabetic conditions in mice and
zebrafish resulted in proteinuria, a condition often related to
diabetes. Serum kynurenine metabolite levels in these animals
were changed showing an increase in the levels of KYNA and
KYN parallel with a decrease in the level of AA, suggesting a
shift in the KP. Depletion of NAD+ was found to have a negative
effect on insulin sensitivity and also on the proper functioning of
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podocytes. Based on these findings, decreased expression and/or
genetic inhibition of KMO leading to decreased production
of NAD+ was proposed to contribute to diabetes related
proteinuria (43).
In a recent study of Zheng et al., genetic deletion of KMO was
found to be protective against ischemia-reperfusion injury (IRI)
induced acute kidney injury (AKI). KMO−/−mice showed better
kidney function and significantly diminished tubular necrosis in
the kidney tissue than KMO+/+ animals. Similarly, significantly
less neutrophil granulocyte infiltration was measured in the renal
tissue uponKMOdeficiency. Following IRI, the levels of Trpwere
significantly decreased in both KMO−/− and KMO+/+ groups
compared to animals without IRI. IRI also led to increased levels
of the protective KYNA in KMO−/− mice. The plasma level of
3-HK was elevated followed by IRI in KMO expressing animals,
however, such changes were not observed in KMO deficient
animals. Considering the ROS generating, thus potentially pro-
apoptotic properties of 3-HK, it could be concluded that genetic
ablation of KMO, followed by decreased production of 3-HK,
carry potential for preventing AKI after IRI (44).
Despite that these findings suggest promising results
upon KMO ablation, inhibition of the enzyme might hold
disadvantages as well. Recently Badawy has proposed, that
QUIN is the most potent immunosuppressant KP metabolite,
and it plays antagonistic role with the anti-inflammatory KNYA
(148). Though downregulation of KMO might be beneficial
in regards to elevated anti-inflammatory KYNA production,
this would be accompanied by a diminished amount of the
immunosuppressant QUIN. This situation clearly represents
the complexity and delicate balance of the pathway and its
metabolites, and raises further difficulties to be overcome.
ASSOCIATIONS BETWEEN GENE
VARIATIONS LEADING TO CHANGES IN
KP ENZYME FUNCTION AND HUMAN
DISEASES
With the advent of new generation sequencing, a growing body of
data is accumulating on polymorphisms in the human genome.
It is, however, a great challenge to establish causality between
genomic changes and the appearance and/or progression of
specific diseases, and associations between genetic variants with
disease states remain mostly obscure. Variants of genes encoding
KP enzymes have been found to occur in frequencies differing
between patient groups of specific diseases and samples of healthy
population (1). Association of IDO variants have been suggested
with depression (48, 149, 150) and autoimmune diseases such
as systemic sclerosis (151) and Crohn’s disease (152). TDO
variants are believed to be associated with hypertryptophanemia
(153) and psychiatric disorders such as Tourette syndrome (154)
and autism (155). KMO mutations were found to be related
to psychiatric diseases such as schizophrenia (156–161), bipolar
disorder (162), and postpartum depression (163), and also in
multiple sclerosis (164). Variations of the AADAT gene encoding
the KATII enzyme were found to be associated with bacterial
meningitis (165–167), changes in KYNU are believed to be
related to essential hypertension (168, 169) and xanthurenic
aciduria (170). An SNP in the HAAO gene encoding 3-HAO was
found to be associated to hypospadiasis by a so far unknown
mechanism (171), and changes in ACMSD were proposed to be
linked with Parkinson’s disease (PD) (172).
Despite the numerous findings pointing to possible
associations of specific SNPs with specific diseases, only in
very few cases are known where a change in a gene sequence
results in a change in the activity of an enzyme connected to
the disease, thus indicating direct causal link between gene
variant(s) and disorder(s). In the following part of this section
we summarize findings of those naturally occurring variations
in KP genes that disturb the activity of the encoded enzyme and
thus are proposedly linked to human diseases in which immune
functions are altered.
Several IDO gene variants -present in the population with
differing frequencies-have been shown to impact enzyme
function (173). Nonetheless, there are only a very limited number
of studies on these variants, despite the great clinical relevance
they might have in a better understanding the pathomechanisms
of specific diseases.
Systemic sclerosis (SSc), a connective tissue disease of which
a hallmark is autoimmunity, is indicated by the infiltration of
circulating antibodies and activated T cells in the affected tissues
(151). Underlying the role of altered immune response in the
disease are findings of disequilibrium of the pro-inflammatory
Th17 and regulatory T cell functions in patients with SSc (174).
Considering the T cell modulatory effects of IDO, one can easily
foresee the involvement of the enzyme in the disease. Tardito
and colleagues investigated the occurrence of five IDO SNPs in
SSc (151). Three of these nucleotide alterations are located in the
coding region of the IDO gene, which all result in amino acid
changes, the other two are in the intronic regions. The frequency
of the 5 SNPs in the worldwide population vary between 1 and 22
percent, and each occur both in homo- and heterozygous forms
(based on data of www.ensembl.org). In the case of four out of
the five SNPs involved in this study there were no observable
frequency differences in their appearance among groups of SSc
and control samples.
A comparison of the frequency of SNP rs7820268 between
a group of SSc patients and a matching control group of
healthy controls revealed significant difference (151). Rs7820268
is a change of a C to T within intron 5 of the IDO
gene. The minor allele is present in 22 percent of the
population worldwide with 37 percent as the highest population
minor allele frequency (based on data of www.ensembl.org).
The frequency of T allele was significantly higher among
patients compared to healthy controls, and similarly higher
were the frequencies of both genotypes carrying the T allele
(TT and TC). By comparing the suppression activity of
T regulatory cells of patients with at least one T allele
to those homozygous for the C allele, it was shown that
CD8+ Treg suppression activity was impaired in individuals
carrying the minor (T) allele. The authors concluded that the
rs7820268 IDO SNP possibly affects IDO expression and/or
activity in a certain type of immune cells, e.g., DCs, which,
via cell-to-cell crosstalk affect the suppressive function of
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CD8+ Treg cells leading to the evolution of autoimmune
processes (151).
Association of IDO gene variants with another autoimmune
disease, Crohn’s disease (CD), has been reported by Lee et al.
(152). CD is a chronic inflammatory bowel disease, which
includes the involvement of the gastrointestinal tract and often
several extraintestinal manifestations, further worsening the
phenotype. In CD the expression of IDO1 was found to be
upregulated, and the activity of the enzyme was found to be
in positive correlation with disease severity and inflammatory
markers such as erythrocyte sedimentation rate and C-reactive
protein (175). A comparison of the frequencies of 6 different
IDO1 variants among CD patients and healthy controls did not
reveal significant differences, nevertheless the higher frequencies
of three of the investigated variants were found to be associated
with the severity of the disease (152). Both rs35059413 and
rs35099072 are a C to T nucleotide change (indicated in reverse
orientation) resulting in a Ala to Thr and Arg to His amino
acid change in the 4th and 77th amino acid position of the
protein, respectively (based on data of www.ensembl.org). The
third variant is a C to A nucleotide change in exon 7. Patients
carrying any of these three coding IDO1 gene variants were more
likely to show extraintestinal manifestations such as arthritis,
uveitis, and perianal disease, indicators of CD severity. Serum
KYN/Trp ratio, that is an indicator of IDO activity, revealed a
decrease in enzyme activity in patients possessing IDO1 SNPs.
These findings strongly support the existence of an association
between a more severe disease phenotype and a decrease in IDO1
activity which is likely to originate from mutations of the IDO
gene (152).
Investigation of genetic variants of another KP gene, AADAT,
that encodes KATII, revealed that in a SNP (rs1480544), a
C to T change in the intronic region of the gene might
be associated with bacterial meningitis (BM) (165). The
minor allele was found to be more frequent among patients
suffering from the disease than in healthy volunteers. The
TT genotype was found to be accompanied by a decrease in
several inflammatory markers in the blood, such as TNFα,
IL1β, and IL6, and a diminished immune cell number in
the cerebrospinal fluid (CSF) (165). These findings led to the
hypothesis that this genetic variant could affect the course of
the infection by influencing the recruitment of immune cells
at the site of infection and the production of inflammation-
related cytokines. Further studies focusing on this genetic variant
revealed that in individuals with the TT genotype an increased
level of KYNA and an elevation in the level of an anti-
inflammatory cytokine, IL-10, were observed compared to those
carrying the CC genotype (166). This led to the conclusion
that BM patients bearing this AADAT SNP might expect a
better disease outcome due to a less excessive inflammatory
response. As the SNP is located in a putative exonic silencer,
it is hypothesized that it leads to enhanced AADAT mRNA
production and consequently to an increase in the amount
of protein produced (166, 176). As a consequence, production
of the neuroprotective and antioxidant KYNA is increased in
carriers of the SNP, further alleviating neuronal damage caused
by infection (166).
CONCLUSIONS
In light of the large number of metabolites that are able to
evoke neurotoxic vs. neuroprotectant, ROS generating vs.
antioxidant, pro- vs. anti-inflammatory effects, it is no wonder
that alterations of the KP have been linked to disease states.
Indeed, altered kynurenine production has been shown in
several neurodegenerative (177–179), psychiatric (180), and
inflammatory diseases (181). Several of these ailments are
characterized by altered immune functions, primarily as the
result of altered levels of specific metabolites resulting from
a change in the activity of key enzymes of the pathway such
as IDO, TDO, or KMO. Interfering in the pathway in order
to restore the imbalances of kynurenine metabolites could be
a feasible way of ameliorating symptoms and reducing the
progression of disease states. Results obtained using animal
models indicate that frequently, though not exclusively, specific
enzyme activity at either normal or increased levels could be
the culprit behind unwanted immune reactions. On the other
hand, this might offer possibilities to restore normal function
by downregulating specific genes. The emerging technique of
genetic therapy is a promising therapeutic approach that has
been or is currently attempted in a regimen of diseases: e.g.,
neurological disorders such as Huntington’s disease [IONIS-
HTTRx; ClinicalTrials.govidentifier: NCT02519036; (182)] and
spinal muscular atrophy (SMA) (140), immunological diseases
as severe combined immune deficiency due to adenosine-
deaminase deficiency [ADA-SCID; (183)], cardiovascular
diseases (184) and malignant diseases like acute lymphoblastic
leukemia (185) or non-Hodgkin lymphoma (186). In most cases
genetic therapy is viewed as a technology by which entire genes
or gene segments are inserted or removed to/from the genome.
However, an effective genetic approach could be selective
inhibition of the expression of a specific gene at a given tissue
type and/or in a specific time frame. Results from animal models
suggest that this could be a possibility in the cases of several
diseases in which an overreaction of the immune response
might be ameliorated by inhibiting KP enzyme activity locally
and temporarily.
Regarding the modulation of immune function via the KP
by genetic interventions, the first and rate limiting enzyme,
IDO has been in the focus of research. Most of these studies
use animal models, primarily mice knockouts. Several studies,
on the other hand, were performed by modifying KP enzyme
expression in animal or human cells in tissue culture. Inhibition
of the enzyme at a genetic level was found to be beneficial
in animal models of bacterial (2) and viral (3, 4) infections,
immune modulation following organ transplant (19, 20) and
diseases in which chronic inflammation plays a crucial role,
such as DR (27), atherosclerosis (28), AAA (29, 30) and
metabolic changes linked to obesity (31). Inhibition of the
enzyme is also a promising way of interfering in tumor mediated
immunological changes, thus restoring anti-tumor immunity
(33, 34, 36, 45, 46). Genetic inhibition of a functional ortholog
of the enzyme, TDO, was also found to be beneficial in the
combat against tumors (38). On the other hand, cell culture
studies also revealed antimicrobial effects of enhanced expression
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of the enzyme (40). Genetic modulation of another KP enzyme,
KMO has also proven to be two sided: inhibition was found
to be protective against EMCV infection in a mouse model
of viral myocarditis (41), however, lack of KMO was reported
to lead to autoimmune disease exacerbation (42) and also
caused malfunction of podocytes in the kidney and consequent
proteinuria (43).
Genome wide association studies have proposed several
genetic variants of genes encoding KP enzymes to be associated
with human diseases. However, there are only a handful of
studies on the effects of these genetic changes on enzyme
function. Thus, establishing cause-case relations between specific
SNPs and disease development requires a great amount of
further work. Nonetheless, findings obtained from genetically
modified animal studies suggest that intervention in the KP by
genetic modulation might be a promising therapeutic approach.
Thus, research aimed at uncovering the effects of naturally
occurring gene variations on the expression and function of the
encoded enzymes is highly warranted, as results of these studies
combined with preclinical findings can help in the identification
of novel therapeutic targets and in the development of suitable
therapeutic approaches.
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